Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tavneos

- PMLiVE

Kite and Epic Bio announce cancer cell therapy collaboration agreement

The partnership centres around Epic Bio’s proprietary gene regulation platform

- PMLiVE

Roche and Monte Rosa enter molecular glue degrader partnership worth over $2bn

The companies will work on therapies for targets in cancer and neurological diseases

- PMLiVE

Amgen presents new findings for Uplizna in neuromyelitis optica spectrum disorder

The rare and debilitating disease affects approximately one to ten per 100,000 people

- PMLiVE

EDX Medical Group develops multi-disease ‘point-of-care’ rapid tests for cancer, infections and cardiovascular conditions

The development follows the Group’s acquisition of Hutano Diagnostics

- PMLiVE

Pfizer’s Litfulo approved by EC for adults and adolescents with severe alopecia areata

The autoimmune disease affects approximately 147 million people globally

- PMLiVE

Amgen free to proceed with $27.8bn Horizon acquisition following US FTC settlement

The FTC filed an antitrust lawsuit against Amgen earlier this year in a bid to block the transaction

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

- PMLiVE

Medscape Oncology and American Society of Clinical Oncology Collaborate to Offer Cancer-Specific Training to Multidisciplinary Members of the Oncology Care Team

This week Medscape Oncology announced an exciting collaboration with  ASCO® which you read on the Cision PR news wire here or below:The American Society of Clinical Oncology (ASCO®), a leader at...

Medscape Education Global

- PMLiVE

Amgen’s Lumakras shows promise in phase 3 lung cancer study

The company has also presented results from a study of Lumakras in colorectal cancer

- PMLiVE

Amgen reports positive results for inflammatory disease drug Otezla in psoriatic arthritis

The inflammatory condition is estimated to affect nearly 38 million people worldwide

- PMLiVE

Amgen and TScan Therapeutics partner to identify new Crohn’s disease targets

Inflammatory bowel disease affects nearly one in every 100 people in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links